Medical device maker Dexcom said the use of its continuous glucose monitor, G7, led to improved blood sugar control in ...

A new study presented at the American Diabetes Association found that Dexcom’s G7 continuous glucose monitor significantly ...

In the lead-up to the American Diabetes Association’s Scientific Sessions, Dexcom announced an acquisition and Insulet rolled ...

DexCom posts steady profits and global reach, while Insulet surges ahead with rapid revenue growth and a focused product line ...

San Diego device maker Dexcom has received the first FDA clearance for a continuous glucose monitor that doesn’t require a doctor’s prescription. The U.S. Food and Drug Administration cleared Dexcom’s ...

NEW YORK (PIX11) — A medical company is alerting the public after some of its continuous glucose monitoring devices were ...

Dexcom says stolen G7 sensors from two scrapped lots were sold through unauthorized channels, creating infection and reading-failure risks.

The diabetes tech firm has identified two lots of G7 sensors that have been stolen, sold and used by customers.

Abbott Laboratories (NYSE: ABT) and Dexcom (NASDAQ: DXCM) are two leading medical device companies that compete against one another in the market for continuous glucose monitoring (CGM) systems. They ...

DexCom is a medical device leader that develops and markets continuous glucose monitoring (CGM) systems to track blood glucose levels in real time. DexCom is a leader in this niche. And while some ...

However, DXCM stock is down 19.3% from its 52-week high of $89.98 touched on July, 30. Moreover, DXCM declined marginally ...

DexCom, Inc. DXCM is well-positioned for growth in the coming quarters, supported by the significant potential of the ...